The Laboratory Research Division (LRD) of the EORTC currently consists of five Groups with expertise that includes pre-clinical drug development, all aspects of cancer pharmacology, clinically-relevant receptor and biomarker studies, functional imaging and contemporary pathology. The LRD provides a Europewide resource for cancer clinical trials with particular expertise in the evolving field of translational research. In the development of therapies designed to exploit the molecular and cellular pathology of cancer, it is essential that translational research is included at all stages and the EORTC, through the LRD, has access to such expertise. In addition to providing support for drug development and clinical trials, the LRD represents a ...
AbstractAfter more than 30 years of clinical and translational research, and having contributed to l...
Head and neck squamous cell cancer (HNSCC) is the sixth leading cause of cancer-related deaths world...
Head and neck squamous cell cancer (HNSCC) is the sixth leading cause of cancer-related deaths world...
Early drug development at EORTC has always been subject to structural changes to adapt to the rapid ...
The role of the pathologist in clinical trials (CT) is focused on three activities: pathology review...
AbstractEORTC Headquarters plays a unique role in coordinating and supporting large-scale pan-Europe...
Improvement in cancer care is possible by applying new treatment modalities, which are emerging from...
Item does not contain fulltextThe EORTC Leukemia Group comprises more than 45 qualified haematology ...
textabstractThe landscape for cancer research is profoundly different today from that only one...
AbstractThe increasing demand for personalized cancer therapy requires a strong, intense, and contin...
AbstractThe EORTC Pharmacology and Molecular Mechanism Group (PAMM) focuses on applied research to t...
The EORTC Leukemia Group comprises more than 45 qualified haematology centres in Europe. The group p...
textabstractAfter more than 30 years of clinical and translational research, and having contributed ...
Head and neck squamous cell cancer (HNSCC) is the sixth leading cause of cancer-related deaths world...
Item does not contain fulltextThe EORTC Melanoma Group (MG) was founded in 1969 by both clinicians a...
AbstractAfter more than 30 years of clinical and translational research, and having contributed to l...
Head and neck squamous cell cancer (HNSCC) is the sixth leading cause of cancer-related deaths world...
Head and neck squamous cell cancer (HNSCC) is the sixth leading cause of cancer-related deaths world...
Early drug development at EORTC has always been subject to structural changes to adapt to the rapid ...
The role of the pathologist in clinical trials (CT) is focused on three activities: pathology review...
AbstractEORTC Headquarters plays a unique role in coordinating and supporting large-scale pan-Europe...
Improvement in cancer care is possible by applying new treatment modalities, which are emerging from...
Item does not contain fulltextThe EORTC Leukemia Group comprises more than 45 qualified haematology ...
textabstractThe landscape for cancer research is profoundly different today from that only one...
AbstractThe increasing demand for personalized cancer therapy requires a strong, intense, and contin...
AbstractThe EORTC Pharmacology and Molecular Mechanism Group (PAMM) focuses on applied research to t...
The EORTC Leukemia Group comprises more than 45 qualified haematology centres in Europe. The group p...
textabstractAfter more than 30 years of clinical and translational research, and having contributed ...
Head and neck squamous cell cancer (HNSCC) is the sixth leading cause of cancer-related deaths world...
Item does not contain fulltextThe EORTC Melanoma Group (MG) was founded in 1969 by both clinicians a...
AbstractAfter more than 30 years of clinical and translational research, and having contributed to l...
Head and neck squamous cell cancer (HNSCC) is the sixth leading cause of cancer-related deaths world...
Head and neck squamous cell cancer (HNSCC) is the sixth leading cause of cancer-related deaths world...